Ana M. P.
- Country
- Spain
- Department
- Clinical Hematology
Research Overview
- Phase 3 Randomized Double‑Blind Trial of Orelabrutinib Combined with Rituximab and Bendamustine versus Rituximab‑Bendamustine in Treatment‑Naïve Mantle Cell Lymphoma
- Phase 3 Randomized Study of Tafasitamab, Lenalidomide, and Rituximab in Relapsed/Refractory Follicular and Marginal Zone Lymphoma
- Phase II Multicentric Trial Evaluating Ibrutinib and Rituximab Efficacy and Safety in Indolent Mantle Cell Lymphoma
Data & Insights
Has run more than one trial at 105 of 283 partner sites.
Specializations
Chronic Lymphocytic Disorders
The investigator specializes in treating chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), with particular focus on innovative combination therapies using targeted agents.
- Novel therapeutic combinations with BTK inhibitors
- Minimal residual disease-guided treatment approaches
- Fixed-duration treatment strategies
Their research explores personalized treatment durations based on individual patient response markers.
Follicular Lymphoma
The investigator conducts research in follicular lymphoma treatment, particularly focusing on cases with specific prognostic indicators such as FLIPI 2-5 scores.
- Immunotherapy combinations
- Novel antibody-based treatments
- Risk-adapted therapeutic approaches
Their work encompasses both previously untreated and relapsed/refractory disease states.
Marginal Zone Lymphoma
The investigator's expertise extends to marginal zone lymphoma (MZL), exploring innovative therapeutic combinations including immunomodulatory agents and targeted therapies.
- Combined immunotherapy approaches
- Treatment strategies for refractory disease
- Novel drug combinations
Their research focuses on improving outcomes in resistant disease scenarios.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.